公开(公告)号：US10512651B2

公开(公告)日：2019-12-24

申请号：US15506421

申请日：2015-08-21

Applicant: STC.UNM

Inventor： Ellen Janine Beswick

IPC: A61K31/554 ,  A61K38/00 ,  A61K31/553 ,  A61K31/167 ,  A61K45/06 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/551 ,  A61P35/00 ,  A61K31/165

Abstract: The present invention relates to the discovery that MK2 is highly expressed in cancer tissue and the inhibition of MK2 using an MK2 inhibitor represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. MK2 inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.

公开(公告)号：US20160368980A1

公开(公告)日：2016-12-22

申请号：US14832031

申请日：2015-08-21

Applicant: STC.UNM

Inventor： Katherine Theresa Morris ,  Ellen Janine Beswick

IPC: C07K16/24 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/243 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/76

Abstract: The present invention relates to the discovery that granulocyte colony stimulating factor (G-CSF) as well as granulocyte colony stimulating factor receptor (G-CSFR) are highly expressed in cancer tissue and the inhibition of G-CSF using a G-CSF inhibitor, which term includes inhibitors of the G-CSF receptor, represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. G-CSF inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.

Abstract translation: 本发明涉及在癌组织中高度表达粒细胞集落刺激因子（G-CSF）以及粒细胞集落刺激因子受体（G-CSFR）的发现，并且使用G-CSF抑制剂抑制G-CSF， 该术语包括G-CSF受体的抑制剂，代表治疗癌症的可行方法，包括耐药性癌症，转移性癌症和复发性癌症。 本文所述的G-CSF抑制剂可以单独使用或与至少一种另外的抗癌剂组合用于治疗癌症。